Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells

Blood blood.2024024846.

https://doi.org/10.1182/blood.2024024846

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

Sivasubramanian Baskar, Haiyong Peng, Christoph Rader, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 9989–9990.

https://doi.org/10.1182/blood-2022-166681

Published: 2022

Journal Articles

To Catch a Killer: Delineating the Mechanistic Role of Siglec-6, a Novel Glycoprotein Target, for the Treatment of Chronic Lymphocytic Leukemia

Jessica Nunes, Ann Ventura, Kevan Zapolnik, Xiaokui Mo, Liwen Zhang, John C. Byrd, Christoph Rader, Natarajan Muthusamy

Blood (2022) 140 (Supplement 1): 9836–9837.

https://doi.org/10.1182/blood-2022-171078

Published: 2022

Journal Articles

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Maissa Mhibik, Erika M. Gaglione, David Eik, Ellen K. Kendall, Amy Blackburn, Keyvan Keyvanfar, Maria Joao Baptista, Inhye E. Ahn, Clare Sun, Junpeng Qi, Christoph Rader, Adrian Wiestner

Blood (2021) 138 (19): 1843–1854.

https://doi.org/10.1182/blood.2020009686

Published: 2021

Includes: Supplemental data

Journal Articles

Defining the Biochemical Role of Sialic Acid-Binding Immunoglobulin-like Lectin-6 in Adhesion and Migration in Chronic Lymphocytic Leukemia

Jessica Nunes, Ann Ventura, Kevan Zapolnik, Eileen Hu, Liwen Zhang, Xiaokui Mo, John C. Byrd, Christoph Rader, Raj Muthusamy

Blood (2021) 138 (Supplement 1): 2623.

https://doi.org/10.1182/blood-2021-152477

Published: 2021

Journal Articles

A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib

Maissa Mhibik, PhD, Erika M Gaglione, Amy Blackburn, Keyvan Keyvanfar, Clare Sun, MD, Inhye E Ahn, MD, Maria Joao Baptista, Junpeng Qi, PhD, Christoph Rader, PhD, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 2861.

https://doi.org/10.1182/blood-2019-126186

Published: 2019

Journal Articles

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Swagata Goswami, MSc, Chi-Ling Chiang, PhD, Kevan Zapolnik, BS, Zhiliang Xie, James L. Lee, PhD, Sivasubramanian Baskar, Christoph Rader, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Bhavana Bhatnagar, DO, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3798.

https://doi.org/10.1182/blood-2019-128828

Published: 2019

Journal Articles

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model

Chi-Ling Chiang, Swagata Goswami, Frank W. Frissora, Zhiliang Xie, Pearlly S. Yan, Ralf Bundschuh, Logan A. Walker, Xiaomeng Huang, Rajeswaran Mani, Xiaokui M. Mo, Sivasubramanian Baskar, Christoph Rader, Mitch A. Phelps, Guido Marcucci, John C. Byrd, L. James Lee, Natarajan Muthusamy

Blood (2019) 134 (5): 432–444.

https://doi.org/10.1182/blood.2018882290

Published: 2019

Includes: Supplemental data

Journal Articles

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Hannah R. Robinson, Junpeng Qi, Erika M. Cook, Cydney Nichols, Eman L. Dadashian, Chingiz Underbayev, Sarah E. M. Herman, Nakhle S. Saba, Keyvan Keyvanfar, Clare Sun, Inhye E. Ahn, Sivasubramanian Baskar, Christoph Rader, Adrian Wiestner

Blood (2018) 132 (5): 521–532.

https://doi.org/10.1182/blood-2018-02-830992

Published: 2018

Includes: Supplemental data

Journal Articles

Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eileen Hu, BS, Priscilla Do, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Haiyong Peng, PhD, Lorenz Waldmeier, PhD, Roger Beerli, PhD, Christoph Rader, PhD, Ulf Grawunder, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 3017.

https://doi.org/10.1182/blood.V130.Suppl_1.3017.3017

Published: 2017

Journal Articles

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Chi-Ling Chiang, MS, Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Zhiliang Xie, Xiaomeng Huang, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, PhD, Mitch A. Phelps, PhD, Guido Marcucci, MD, John C. Byrd, MD, James L. Lee, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 4981.

https://doi.org/10.1182/blood.V130.Suppl_1.4981.4981

Published: 2017

Journal Articles

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Hannah R. Robinson, BA, Junpeng Qi, PhD, Sivasubramanian Baskar, PhD, Erika Cook, BA, Inhye E. Ahn, MD, Sarah E. M. Herman, PhD, Christoph Rader, PhD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 799.

https://doi.org/10.1182/blood.V130.Suppl_1.799.799

Published: 2017

Journal Articles

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Chi-Ling Chiang, Frank W Frissora, Zhiliang Xie, Xiaomeng Huang, Rajeswaran Mani, DVM, Sivasubramanian Baskar, Christoph Rader, Kenneth K. Chan, Guido Marcucci, MD, John C. Byrd, MD, L. James Lee, Natarajan Muthusamy, DVM, PhD

Blood (2015) 126 (23): 1743.

https://doi.org/10.1182/blood.V126.23.1743.1743

Published: 2015

Journal Articles

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Rajeswaran Mani, DVM, Yicheng Mao, PhD, Frank W Frissora, M.S., Chi-ling Chiang, Jiang Wang, Yuan Zhao, Yun Wu, Bo Yu, Ph.D., Ribai Yan, Xiaokui Mo, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D., Mitch A. Phelps, PhD, Robert J. Lee, Ph.D, Ching-Shih Chen, PhD, James Lee, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 4168.

https://doi.org/10.1182/blood.V122.21.4168.4168

Published: 2013

Journal Articles

Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion

Brian C Shaffer, MD, Judith Leitner, PhD, Adrian Wiestner, MD, PhD, Michael R. Bishop, MD, Steven Z. Pavletic, MD, Ronald E. Gress, MD, Peter Steinberger, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D.

Blood (2012) 120 (21): 1349.

https://doi.org/10.1182/blood.V120.21.1349.1349

Published: 2012

Journal Articles

Naïve CD4+ T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ ROR1-CAR T Cells

Michael Hudecek, MD, Maria-Teresa Lupo-Stanghellini, MD, Paula Kosasih, BSc, Jeannette Bet, MSc, Paulina Paszkiewicz, MSc, David G. Maloney, MD, PhD, Michael C. Jensen, MD, Christoph Rader, Ph.D., Stanley R. Riddell, MD

Blood (2011) 118 (21): 643.

https://doi.org/10.1182/blood.V118.21.643.643

Published: 2011

Journal Articles

Fcμ-Receptor (FcμR; TOSO/ FAIM3 ) Mediated Internalization of Antibody-Drug Conjugates: A Novel Approach to Selectively Target Chronic Lymphocytic Leukemia Cells

Berengere Vire, Ph.D., Alexandre David, Ph.D., Joshua D Thomas, Ph.D., Terrence R Burke, Jr., Ph.D., Christoph Rader, Ph.D., Adrian Wiestner, MD, PhD

Blood (2011) 118 (21): 734.

https://doi.org/10.1182/blood.V118.21.734.734

Published: 2011

Journal Articles

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

Davide Bagnara, Matthew S. Kaufman, Carlo Calissano, Sonia Marsilio, Piers E. M. Patten, Rita Simone, Philip Chum, Xiao-Jie Yan, Steven L. Allen, Jonathan E. Kolitz, Sivasubramanian Baskar, Christoph Rader, Hakan Mellstedt, Hodjattallah Rabbani, Annette Lee, Peter K. Gregersen, Kanti R. Rai, Nicholas Chiorazzi

Blood (2011) 117 (20): 5463–5472.

https://doi.org/10.1182/blood-2010-12-324210

Published: 2011

Includes: Supplemental data

Journal Articles

DARTs take aim at BiTEs

Christoph Rader

Blood (2011) 117 (17): 4403–4404.

https://doi.org/10.1182/blood-2011-02-337691

Published: 2011

Journal Articles

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

Patricia Pérez-Galán, Helena Mora-Jensen, Marc A. Weniger, Arthur L. Shaffer, III, Edgar G. Rizzatti, Colby M. Chapman, Clifton C. Mo, Lawrence S. Stennett, Christoph Rader, Poching Liu, Nalini Raghavachari, Maryalice Stetler-Stevenson, Constance Yuan, Stefania Pittaluga, Irina Maric, Kieron M. Dunleavy, Wyndham H. Wilson, Louis M. Staudt, Adrian Wiestner

Blood (2011) 117 (2): 542–552.

https://doi.org/10.1182/blood-2010-02-269514

Published: 2011

Includes: Supplemental data

NARROW

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells

Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

To Catch a Killer: Delineating the Mechanistic Role of Siglec-6, a Novel Glycoprotein Target, for the Treatment of Chronic Lymphocytic Leukemia

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Defining the Biochemical Role of Sialic Acid-Binding Immunoglobulin-like Lectin-6 in Adhesion and Migration in Chronic Lymphocytic Leukemia

A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion

Naïve CD4+ T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ ROR1-CAR T Cells

Fcμ-Receptor (FcμR; TOSO/ FAIM3 ) Mediated Internalization of Antibody-Drug Conjugates: A Novel Approach to Selectively Target Chronic Lymphocytic Leukemia Cells

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

DARTs take aim at BiTEs

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only